Shelton Capital Management’s Biogen BIIB Stock Holding History

Shelton Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,444	Closed	-$1.32M	–	713
2025 Q3	$1.32M	Sell	9,444 -7,924	-46%	-$1.07M	0.03%	249
2025 Q2	$2.18M	Sell	17,368 -3,541	-17%	-$441K	0.05%	221
2025 Q1	$2.86M	Sell	20,909 -292	-1%	-$41.7K	0.07%	204
2024 Q4	$3.24M	Hold	21,201	–	–	0.08%	187
2024 Q3	$4.11M	Sell	21,201 -100	-0.5%	-$20.9K	0.11%	175
2024 Q2	$4.94M	Buy	21,301 +112	+0.5%	+$24.3K	0.13%	148
2024 Q1	$4.57M	Hold	21,189	–	–	0.13%	172
2023 Q4	$5.48M	Buy	21,189 +538	+3%	+$132K	0.17%	145
2023 Q3	$5.31M	Buy	20,651 +3,488	+20%	+$933K	0.19%	129
2023 Q2	$4.89M	Sell	17,163 -2,270	-12%	-$676K	0.18%	128
2023 Q1	$5.4M	Buy	19,433 +12,633	+186%	+$3.5M	0.23%	104
2022 Q4	$1.88M	Sell	6,800 -16,512	-71%	-$4.66M	0.2%	169
2022 Q3	$6.22M	Buy	23,312 +4,956	+27%	+$1.05M	0.3%	86
2022 Q2	$3.74M	Sell	18,356 -200	-1%	-$40.9K	0.17%	139
2022 Q1	$3.91M	Sell	18,556 -100	-0.5%	-$21.7K	0.14%	158
2021 Q4	$4.48M	Hold	18,656	–	–	0.16%	146
2021 Q3	$5.28M	Buy	18,656 +63	+0.3%	+$20.6K	0.21%	107
2021 Q2	$6.44M	Sell	18,593 -2,900	-13%	-$879K	0.24%	93
2021 Q1	$6.01M	Buy	21,493 +8,137	+61%	+$2.19M	0.21%	106
2020 Q4	$3.27M	Sell	13,356 -446	-3%	-$115K	0.15%	145
2020 Q3	$3.92M	Sell	13,802 -724	-5%	-$202K	0.16%	145
2020 Q2	$3.89M	Sell	14,526 -1,242	-8%	-$373K	0.21%	96
2020 Q1	$4.99M	Sell	15,768 -9,406	-37%	-$2.85M	0.36%	56
2019 Q4	$7.47M	Buy	25,174 +8,278	+49%	+$2.3M	0.41%	52
2019 Q3	$3.93M	Sell	16,896 -3,770	-18%	-$878K	0.23%	85
2019 Q2	$4.83M	Buy	20,666 +15,730	+319%	+$3.63M	0.28%	68
2019 Q1	$20.9K	Sell	4,936 -15,545	-76%	-$4.89M	0.08%	230
2018 Q4	$6.16M	Sell	20,481 -343	-2%	-$109K	0.42%	54
2018 Q3	$7.36M	Sell	20,824 -48	-0.2%	-$16.5K	0.42%	52
2018 Q2	$6.06M	Buy	20,872 +48	+0.2%	+$13.5K	0.38%	57
2018 Q1	$5.7M	Buy	20,824 +1,744	+9%	+$541K	0.37%	60
2017 Q4	$6.08M	Sell	19,080 -57	-0.3%	-$18.3K	0.39%	55
2017 Q3	$5.99M	Hold	19,137	–	–	0.4%	50
2017 Q2	$5.19M	Buy	19,137 +1,354	+8%	+$358K	0.37%	61
2017 Q1	$4.86M	Buy	17,783 +1,813	+11%	+$513K	0.34%	55
2016 Q4	$4.53M	Hold	15,970	–	–	0.34%	59
2016 Q3	$5M	Sell	15,970 -5	-0%	-$1.48K	0.42%	40
2016 Q2	$3.86M	Buy	15,975 +5	+0%	+$1.32K	0.34%	61
2016 Q1	$4.16M	Buy	15,970 +294	+2%	+$77.7K	0.38%	48
2015 Q4	$4.8M	Sell	15,676 -513	-3%	-$147K	0.46%	41
2015 Q3	$4.72M	Buy	16,189 +1,990	+14%	+$657K	0.52%	35
2015 Q2	$5.74M	Buy	14,199 +716	+5%	+$287K	0.59%	31
2015 Q1	$5.69M	Buy	13,483 +2,811	+26%	+$1.11M	0.62%	28
2014 Q4	$3.62M	Buy	10,672 +1,989	+23%	+$643K	0.42%	44
2014 Q3	$2.87M	Buy	8,683 +1,181	+16%	+$389K	0.39%	58
2014 Q2	$2.37M	Sell	7,502 -206	-3%	-$62K	0.33%	64
2014 Q1	$2.36M	Buy	7,708 +599	+8%	+$190K	0.35%	61
2013 Q4	$1.99M	Buy	7,109 +219	+3%	+$56.6K	0.3%	69
2013 Q3	$1.66M	Buy	6,890 +269	+4%	+$60.2K	0.28%	78
2013 Q2	$1.43M	Buy	+6,621	New	+$1.41M	0.26%	85

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shelton Capital Management's BIIB Position: Q4 2025 in Review

Shelton Capital Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 9,444 shares — an estimated $1.32M sold.

Shelton Capital Management first reported a position in BIIB in Q2 2013 and held it in 50 quarters. The position peaked at $7.47M in Q4 2019. 997 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Shelton Capital Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Shelton Capital Management sold 9,444 Biogen shares in Q4 2025, an estimated $1.32M.
Shelton Capital Management first reported a position in Biogen in Q2 2013 and held it in 50 quarters.
Shelton Capital Management's Biogen position peaked at $7.47M in Q4 2019.
997 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Shelton Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.